Confluence Wealth Management LLC trimmed its stake in shares of Eli Lilly And Co (NYSE:LLY) by 6.6% during the 4th quarter, HoldingsChannel reports. The firm owned 3,319 shares of the company’s stock after selling 235 shares during the quarter. Confluence Wealth Management LLC’s holdings in Eli Lilly And Co were worth $384,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of LLY. Athena Capital Advisors LLC purchased a new position in Eli Lilly And Co during the fourth quarter valued at $26,000. Larson Financial Group LLC purchased a new position in Eli Lilly And Co during the fourth quarter valued at $29,000. Ironwood Financial llc purchased a new position in Eli Lilly And Co during the fourth quarter valued at $30,000. Acima Private Wealth LLC purchased a new position in Eli Lilly And Co during the fourth quarter valued at $33,000. Finally, Essex Investment Management Co. LLC purchased a new position in Eli Lilly And Co during the fourth quarter valued at $34,000. 77.00% of the stock is currently owned by institutional investors and hedge funds.

In related news, SVP Alfonso G. Zulueta sold 4,000 shares of the firm’s stock in a transaction dated Thursday, January 31st. The shares were sold at an average price of $120.00, for a total transaction of $480,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction dated Tuesday, February 19th. The stock was sold at an average price of $122.48, for a total transaction of $25,108,400.00. Following the sale, the insider now owns 117,641,684 shares of the company’s stock, valued at $14,408,753,456.32. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 833,190 shares of company stock valued at $102,388,102. 0.11% of the stock is owned by company insiders.

A number of equities research analysts have recently commented on the stock. Citigroup cut shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 target price for the company. in a research report on Monday, November 26th. Zacks Investment Research cut shares of Eli Lilly And Co from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. Morgan Stanley set a $116.00 target price on shares of Eli Lilly And Co and gave the company a “hold” rating in a research report on Thursday, December 20th. BMO Capital Markets increased their target price on shares of Eli Lilly And Co from $124.00 to $132.00 and gave the company an “outperform” rating in a research report on Monday, December 24th. They noted that the move was a valuation call. Finally, Cantor Fitzgerald reiterated a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Eleven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $113.06.

Eli Lilly And Co stock opened at $123.94 on Friday. Eli Lilly And Co has a 12-month low of $74.51 and a 12-month high of $130.75. The stock has a market cap of $128.33 billion, a P/E ratio of 22.33, a PEG ratio of 2.49 and a beta of 0.33. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a return on equity of 44.66% and a net margin of 13.16%. The firm had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. During the same quarter in the previous year, the business posted $1.14 earnings per share. Eli Lilly And Co’s revenue for the quarter was up 4.5% on a year-over-year basis. As a group, equities research analysts predict that Eli Lilly And Co will post 5.62 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 8th. Investors of record on Friday, February 15th were given a dividend of $0.645 per share. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. This represents a $2.58 annualized dividend and a yield of 2.08%. The ex-dividend date of this dividend was Thursday, February 14th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

ILLEGAL ACTIVITY WARNING: This report was first posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another domain, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this report can be accessed at https://www.dailypolitical.com/2019/03/16/eli-lilly-and-co-lly-holdings-cut-by-confluence-wealth-management-llc.html.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: How to invest in a bear market

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.